Diagnostic industry looks to leverage Covid infra for non-Covid tests

Diagnostic laboratory (lab) chains had created capacities for molecular biology tests in the past two years to cater to a huge surge in demand for Covid testing. Two years and three Covid-19 waves later, lab chains are now working out strategies to utilise these capacities created.
 

Covid revenues are roughly 10 per cent of large lab chains’ turnovers now, claims the industry. At its peak, the contribution from Covid went up to 20-25 per cent. However, several smaller and regional players who sprung up during the pandemic have a far larger pie from Covid testing, and would now find it